Navigation Links
Verenium To Present At The Jefferies 2012 Global Industrial And Aerospace & Defense Conference
Date:7/31/2012

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that James Levine, President and Chief Executive Officer, will present at the upcoming Jefferies 2012 Global Industrial and Aerospace and Defense Conference. The presentation is scheduled to begin at 10:30  a.m. ET on Tuesday, August 7, 2012 and will take place in New York City.

More information about this event, including a live webcast, may be accessed by visiting the "Investors" section of Verenium's website at www.verenium.com.  A webcast replay will be available approximately one hour after the live webcast ends and will be accessible for 90 days following the conference. 

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates, lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets, future financial performance, and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates, dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Sarah Carmody
Manager, Corporate Communications
858-431-8581
sarah.carmody@verenium.com


'/>"/>
SOURCE Verenium
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Verenium To Present At The Deutsche Bank 2012 Clean Tech, Utilities & Power Conference
2. The Gomez Law Firm Launches New Website Representing Victims Of Defective Stryker Hip Replacement Systems
3. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. TMG Health To Present Kip Piper at Thought Leadership Dinner
6. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. La Jolla Pharmaceutical Company Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
8. DATATRAK International, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Cytomedix, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
10. Retina Implant AG Researcher and Trial Patient to Present at International Retina Congress
11. Satori Pharmaceuticals to Present Data Highlighting Promise of Gamma-Secretase Modulators in Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)...  AOTI Inc. announced today that its fully owned ... a New York City Office in Yonkers, New York ... Wound Oxygen (TWO 2 ) homecare therapy. This new East Coast ... Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical Equipment ... Advanced Oxygen Therapy ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... FLINT, Mich. , Aug. 7, 2017 Diplomat ... appointment of Joel Saban as president, effective Aug. ... Paul Urick has decided to pursue other interests and ... period. "During his tenure, Paul has served us in multiple ... Burman,s Specialty Pharmacy in Jun. 2015 and has provided decisive, ...
Breaking Medicine Technology:
(Date:8/16/2017)... Long Island, NY (PRWEB) , ... August 16, 2017 , ... ... assist with IV starts and blood draws. By broadly deploying AccuVein devices, Maury Regional ... technology takes much of the guesswork out of a needle stick and more importantly, ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the ... clubfoot clinics in all 29 Indian states—bringing the country one step closer to eliminating ... Pradesh, the nonprofit organization is on track to enroll 10,000 children in the clubfoot ...
(Date:8/16/2017)... ... August 16, 2017 , ... Fusion Flix Inc., a Telly Award Winning, Non ... and millions of viewers in a partnership with the Amazon Video Direct Streaming Distribution ... available on Blu Ray disc in 2018. Proceeds will be going to further health ...
(Date:8/16/2017)... ... August 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5 star ... The healthcare industry in the United States has undergone major changes over the last ... to have a doctor’s order to get a blood test or other lab work ...
(Date:8/16/2017)... TX (PRWEB) , ... August 16, 2017 , ... ... the United States, named Dr. Douglas J. Harrison, as the new Medical Director of ... be the new facility Medical Director of our Sienna Plantation location,” said Dr. Michael ...
Breaking Medicine News(10 mins):